vs
Ecovyst Inc.（ECVT）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $199.4M、Ecovyst Inc.の約1.4倍）。Ecovyst Inc.の前年同期比売上増加率が高い（34.0% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $22.9M）。過去8四半期でEcovyst Inc.の売上複合成長率が高い（18.7% vs 1.2%）
Ecovyst Inc.は持続可能な特殊材料をグローバルに提供する企業で、高性能触媒と機能性添加剤の開発・製造を行っています。産業製造、消費財、環境保護などの分野の顧客に対し、業務効率化と炭素排出削減を支援するソリューションを提供しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ECVT vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $199.4M | $283.4M |
| 純利益 | — | $46.7M |
| 粗利率 | 23.4% | 55.5% |
| 営業利益率 | 10.9% | 29.1% |
| 純利益率 | — | 16.5% |
| 売上前年比 | 34.0% | -2.4% |
| 純利益前年比 | — | -23.5% |
| EPS（希薄化後） | $0.06 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $199.4M | $283.4M | ||
| Q3 25 | $204.9M | $274.1M | ||
| Q2 25 | $176.1M | $249.5M | ||
| Q1 25 | $143.1M | $296.5M | ||
| Q4 24 | $148.9M | $290.3M | ||
| Q3 24 | $153.9M | $283.8M | ||
| Q2 24 | $154.0M | $267.1M | ||
| Q1 24 | $141.6M | $277.0M |
| Q4 25 | — | $46.7M | ||
| Q3 25 | $-79.3M | $42.2M | ||
| Q2 25 | $6.0M | $47.5M | ||
| Q1 25 | $-3.6M | $50.1M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | $14.3M | $54.4M | ||
| Q2 24 | $8.3M | $49.1M | ||
| Q1 24 | $1.2M | $49.5M |
| Q4 25 | 23.4% | 55.5% | ||
| Q3 25 | 25.4% | 55.3% | ||
| Q2 25 | 22.8% | 56.2% | ||
| Q1 25 | 13.3% | 57.3% | ||
| Q4 24 | 28.9% | 55.5% | ||
| Q3 24 | 29.3% | 55.5% | ||
| Q2 24 | 27.3% | 54.7% | ||
| Q1 24 | 23.5% | 54.8% |
| Q4 25 | 10.9% | 29.1% | ||
| Q3 25 | 13.8% | 29.1% | ||
| Q2 25 | 9.0% | 28.8% | ||
| Q1 25 | -0.7% | 29.8% | ||
| Q4 24 | 15.1% | 31.7% | ||
| Q3 24 | 17.9% | 29.7% | ||
| Q2 24 | 14.1% | 27.0% | ||
| Q1 24 | 9.5% | 29.7% |
| Q4 25 | — | 16.5% | ||
| Q3 25 | -38.7% | 15.4% | ||
| Q2 25 | 3.4% | 19.0% | ||
| Q1 25 | -2.5% | 16.9% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | 9.3% | 19.2% | ||
| Q2 24 | 5.4% | 18.4% | ||
| Q1 24 | 0.9% | 17.9% |
| Q4 25 | $0.06 | $0.97 | ||
| Q3 25 | $-0.69 | $0.86 | ||
| Q2 25 | $0.05 | $0.95 | ||
| Q1 25 | $-0.03 | $1.00 | ||
| Q4 24 | $-0.26 | $1.22 | ||
| Q3 24 | $0.12 | $1.09 | ||
| Q2 24 | $0.07 | $0.98 | ||
| Q1 24 | $0.01 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $197.2M | $62.4M |
| 総負債低いほど良い | $392.6M | $1.0B |
| 株主資本純資産 | $603.4M | $1.8B |
| 総資産 | $1.3B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.65× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $197.2M | $62.4M | ||
| Q3 25 | $82.0M | $119.1M | ||
| Q2 25 | $69.6M | $139.5M | ||
| Q1 25 | $127.5M | $97.9M | ||
| Q4 24 | $131.4M | $50.9M | ||
| Q3 24 | $123.5M | $51.5M | ||
| Q2 24 | $83.3M | $34.3M | ||
| Q1 24 | $103.1M | $46.5M |
| Q4 25 | $392.6M | $1.0B | ||
| Q3 25 | $854.8M | $993.1M | ||
| Q2 25 | $856.6M | $992.7M | ||
| Q1 25 | $859.0M | $992.4M | ||
| Q4 24 | $860.8M | $992.0M | ||
| Q3 24 | $862.7M | $1.1B | ||
| Q2 24 | $862.4M | $1.1B | ||
| Q1 24 | $866.2M | $1.1B |
| Q4 25 | $603.4M | $1.8B | ||
| Q3 25 | $607.9M | $1.8B | ||
| Q2 25 | $692.4M | $1.9B | ||
| Q1 25 | $698.7M | $1.8B | ||
| Q4 24 | $700.5M | $1.8B | ||
| Q3 24 | $729.4M | $1.7B | ||
| Q2 24 | $717.3M | $1.7B | ||
| Q1 24 | $711.4M | $1.7B |
| Q4 25 | $1.3B | $3.5B | ||
| Q3 25 | $1.7B | $3.4B | ||
| Q2 25 | $1.8B | $3.4B | ||
| Q1 25 | $1.8B | $3.4B | ||
| Q4 24 | $1.8B | $3.3B | ||
| Q3 24 | $1.8B | $3.3B | ||
| Q2 24 | $1.8B | $3.3B | ||
| Q1 24 | $1.8B | $3.3B |
| Q4 25 | 0.65× | 0.56× | ||
| Q3 25 | 1.41× | 0.54× | ||
| Q2 25 | 1.24× | 0.54× | ||
| Q1 25 | 1.23× | 0.54× | ||
| Q4 24 | 1.23× | 0.55× | ||
| Q3 24 | 1.18× | 0.61× | ||
| Q2 24 | 1.20× | 0.65× | ||
| Q1 24 | 1.22× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $41.8M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $22.9M | $75.3M |
| FCFマージンFCF / 売上 | 11.5% | 26.6% |
| 設備投資強度設備投資 / 売上 | 9.4% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $69.9M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $41.8M | $78.3M | ||
| Q3 25 | $55.3M | $57.5M | ||
| Q2 25 | $33.0M | $79.0M | ||
| Q1 25 | $10.3M | $61.8M | ||
| Q4 24 | $43.5M | $65.1M | ||
| Q3 24 | $59.9M | $69.8M | ||
| Q2 24 | $10.0M | $54.8M | ||
| Q1 24 | $36.5M | $66.9M |
| Q4 25 | $22.9M | $75.3M | ||
| Q3 25 | $53.2M | $55.4M | ||
| Q2 25 | $7.8M | $78.2M | ||
| Q1 25 | $-14.0M | $58.4M | ||
| Q4 24 | $30.9M | $63.5M | ||
| Q3 24 | $53.6M | $67.8M | ||
| Q2 24 | $-9.3M | $53.6M | ||
| Q1 24 | $19.1M | $63.8M |
| Q4 25 | 11.5% | 26.6% | ||
| Q3 25 | 26.0% | 20.2% | ||
| Q2 25 | 4.4% | 31.3% | ||
| Q1 25 | -9.8% | 19.7% | ||
| Q4 24 | 20.7% | 21.9% | ||
| Q3 24 | 34.9% | 23.9% | ||
| Q2 24 | -6.1% | 20.1% | ||
| Q1 24 | 13.5% | 23.0% |
| Q4 25 | 9.4% | 1.1% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 14.4% | 0.3% | ||
| Q1 25 | 16.9% | 1.2% | ||
| Q4 24 | 8.5% | 0.5% | ||
| Q3 24 | 4.1% | 0.7% | ||
| Q2 24 | 12.5% | 0.4% | ||
| Q1 24 | 12.3% | 1.1% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | 5.52× | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | 4.21× | 1.28× | ||
| Q2 24 | 1.20× | 1.12× | ||
| Q1 24 | 29.90× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
